CD44v8-10 and CD44s Are Age-dependently Expressed in Primary Cultured Papillary Thyroid Carcinoma Cells and Are Associated with Cell Proliferation.


Journal

The Kobe journal of medical sciences
ISSN: 1883-0498
Titre abrégé: Kobe J Med Sci
Pays: Japan
ID NLM: 0413531

Informations de publication

Date de publication:
25 Apr 2019
Historique:
entrez: 26 7 2019
pubmed: 26 7 2019
medline: 28 1 2020
Statut: epublish

Résumé

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, arising from follicular cells, and accounts for more than 80% of all thyroid malignant tumors. Although age is the strongest prognostic factor of PTC, and various cut-off ages (40-55 years) were suggested in previous studies, the molecular mechanisms causing age-related changes of PTC cell proliferation remain unclear. CD44 is a major cell surface receptor for hyaluronate and is known as a cancer stem cell marker. However, the association between CD44 and PTC is still unknown. Therefore, we determined the proliferation of primary cultured cells obtained from patients with PTC, and the CD44 mRNA expression profile to elucidate age-related association of CD44 with PTC. The results showed that cell proliferation was significantly decreased according to age. We also found that CD44v8-10 and CD44 splice variants were expressed dominantly in patients with PTC. Moreover, the CD44v8-10/CD44s mRNA expression ratio was significantly increased according to age, and there was a significant negative correlation between this expression ratio and cell proliferation. Our findings suggest that the CD44v8-10/CD44s expression ratio in PTC cells is useful for screening for aggressive PTC and may provide clinically valuable information.

Identifiants

pubmed: 31341151
pmc: PMC6668591

Substances chimiques

CD44 protein, human 0
Hyaluronan Receptors 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E1-E9

Références

J Pathol. 2000 Nov;192(3):321-7
pubmed: 11054715
J Am Coll Surg. 2000 Dec;191(6):600-6
pubmed: 11129807
EMBO J. 2001 Aug 1;20(15):4194-203
pubmed: 11483522
J Urol. 2002 Mar;167(3):1282-7
pubmed: 11832714
Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45
pubmed: 12511867
Thyroid. 2003 Oct;13(10):949-58
pubmed: 14611704
J Urol. 2004 Jan;171(1):426-30
pubmed: 14665947
Surgery. 2004 Feb;135(2):139-48
pubmed: 14739848
Cancer Sci. 2004 Dec;95(12):930-5
pubmed: 15596040
Cell. 1991 Apr 5;65(1):13-24
pubmed: 1707342
World J Surg. 2007 Apr;31(4):838-48
pubmed: 17347900
EMBO J. 1991 Feb;10(2):343-8
pubmed: 1991450
World J Surg. 2010 Nov;34(11):2570-80
pubmed: 20625728
Cancer Cell. 2011 Mar 8;19(3):387-400
pubmed: 21397861
Thyroid. 2011 Jul;21(7):707-16
pubmed: 21649472
BMC Cancer. 2011 Sep 29;11:418
pubmed: 21957977
World J Surg. 2012 Jun;36(6):1274-8
pubmed: 22270990
Endocr J. 2013;60(4):415-21
pubmed: 23182919
BMC Cancer. 2013 Apr 08;13:182
pubmed: 23565736
Thyroid. 2014 Jan;24(1):27-34
pubmed: 24001104
Endocr J. 2014;61(5):491-7
pubmed: 24553476
Cancer Res Treat. 2016 Jan;48(1):142-52
pubmed: 25779358
Matrix Biol. 2015 Oct;48:55-65
pubmed: 25937513
Front Immunol. 2015 Apr 21;6:182
pubmed: 25954275
J Clin Oncol. 2015 Jul 20;33(21):2370-5
pubmed: 26077238
Int Arch Otorhinolaryngol. 2017 Jan;21(1):38-41
pubmed: 28050206
Surgery. 1988 Dec;104(6):947-53
pubmed: 3194846
Surgery. 1987 Dec;102(6):1088-95
pubmed: 3686348
Mayo Clin Proc. 1986 Dec;61(12):978-96
pubmed: 3773569
J Radiat Res. 1985 Sep;26(3):269-82
pubmed: 4067903
Exp Mol Pathol. 1994 Dec;61(3):203-11
pubmed: 7541370
Am J Med. 1994 Nov;97(5):418-28
pubmed: 7977430
Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8
pubmed: 8256208
Science. 1996 Jan 26;271(5248):509-12
pubmed: 8560266
Oncogene. 1995 Dec 7;11(11):2223-32
pubmed: 8570172
J Clin Oncol. 1996 Apr;14(4):1122-7
pubmed: 8648366
Jpn J Cancer Res. 1996 Dec;87(12):1245-50
pubmed: 9045959
Cancer. 1997 Jun 25;81(3):157-62
pubmed: 9196014
J Natl Cancer Inst. 1998 Feb 18;90(4):307-15
pubmed: 9486817
Pathol Int. 1998 Mar;48(3):184-90
pubmed: 9589486
World J Surg. 1998 Dec;22(12):1237-42
pubmed: 9841750
Int J Cancer. 1998 Dec 18;79(6):560-4
pubmed: 9842962

Auteurs

Takeo Kawai (T)

Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan.
Department of Clinical Laboratory, Kuma Hospital, Kobe, Japan.

Keisuke Iwata (K)

Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan.

Yuna Shinotsuka (Y)

Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan.

Sayaka Kubo (S)

Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan.

Hiroo Masuoka (H)

Department of Surgery, Kuma Hospital, Kobe, Japan.

Tomonori Yabuta (T)

Department of Surgery, Kuma Hospital, Kobe, Japan.

Mitsuyoshi Hirokawa (M)

Department of Diagnostic Pathology, Kuma Hospital, Kobe, Japan.

Hirotoshi Nakamura (H)

Department of Internal Medicine, Kuma Hospital, Kobe, Japan.

Akira Miyauchi (A)

Department of Surgery, Kuma Hospital, Kobe, Japan.

Koichiro Komai (K)

Division of Medical Biophysics, Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH